Subtype
Malignant Uveal Neoplasm
CI-CAN-00001189Explore in graph →
59 active trials1 approved drugs17 evidence items
- NCIt
- C6105
Loading cancer entity…
Subtype
CI-CAN-00001189Explore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (34)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00344799 | Cytogenetic Study of Ocular Melanoma | completed | — | 95 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT04577742 |
| Uveal Melanoma and Brachytheraphy: Long-term Outcomes. |
| completed |
| — |
| 350 |
| Federico II UniversityOTHER |
| 1 |
| Oct 8, 2020 |
| clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | withdrawn | Early Phase 1 | 0 | University of MiamiOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma(SUAVE) | completed | Phase 2 | 124 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00680225 | Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma | completed | Phase 3 | 10 | New England Retina AssociatesOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00398073 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02379000 | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy | unknown | Phase 4 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01974752 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)(SUMIT) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 11 | Jan 5, 2017 | clinicaltrials |
| NCT00705640 | Vaccine Therapy in Treating Patients With Advanced Melanoma(Mel48) | completed | Phase 1 | 45 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00765921 | Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma | completed | Phase 1 | 40 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01251978 | Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) | completed | Phase 2 | 10 | New England Retina AssociatesOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT00351728 | Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone | completed | — | 174 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2016 | clinicaltrials |
| NCT00596362 | Treatment With Intravitreal Avastin for Large Uveal Melanomas | completed | N/A | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases | terminated | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00089063 | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01924923 | New Biopsy Technique for Uveal Melanoma | completed | — | 1 | Greater Houston Retina ResearchOTHER | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00952939 | Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye | completed | — | 150 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT00089206 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 7 | University of VirginiaOTHER | 1 | Dec 19, 2014 | clinicaltrials |
| NCT01377025 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma(STREAM) | unknown | Phase 2 | 200 | Prof. Dr. med. Max. E. ScheulenOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00089219 | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 39 | University of VirginiaOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT00329641 | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Mar 29, 2021source: clinicaltrials